WellMedr review

WellMedr carries the cheapest headline in this ranking — $59 a month — and its own banner attaches the condition in the same sentence: "Lock In $200 OFF Every Month, or $59/mo on 12/month Plans — For Life". That is a twelve-month plan, and there is no month-to-month rate published anywhere on the site to compare it against.

A "month" here is also four weeks. Both plans are described as shipped every four weeks, which is thirteen charges in a year rather than twelve — so the annual cost runs about eight percent above what multiplying the monthly figure by twelve suggests. Neither "Check Eligibility" button reveals a rate either: both hand off to a checkout app that will not render a price without an account.

Several things here are genuinely better than the category norm, and they are the reason this is not simply a warning. WellMedr names the pharmacy that fills the prescription — Mycelium Pharmacy — and names the clinical groups rather than gesturing at them, OpenLoop Healthcare Partners, PC and Reliant. Its tirzepatide card commits in its own words to "Same price regardless of dosage", which is the promise that matters most when you titrate up. And the compounding caveat sits on the pricing page itself as a blunt "Required Safety Notice", not buried in a footer.

It also runs a real brand-name lane on the same list — Ozempic from $1,399 and Zepbound from $1,599, both labeled month-to-month — and an eight-SKU microdose range across oral and injectable routes. Only two of those eight show a price, both $199 a month; the other six publish none.

The marketing needs discounting, though. "ZERO Side Effects", subheaded "Zero side effct for 70%+ of members" — their typo — is the headline of the microdose page, printed on a page that elsewhere carries thyroid warnings. "FDA-regulated pharmacies" runs in the top bar, which is a claim about the pharmacy rather than the drug, a scroll away from the notice conceding the compounded products are not FDA-approved. To the site's credit, its testimonials are disclosed as "Inspired by real patient success stories in similar Telehealth programs" rather than passed off as its own.

Only the tirzepatide card makes the flat-dose promise; the semaglutide card says nothing either way, so on the cheaper molecule the dose basis is unstated. No list of served states exists — "a licensed professional in your state" is the whole of it. WellMedr is clean against the FDA warning-letter index under its brand, its operating entity and both named clinical groups, screened August 10, 2026 with two passing controls.